您好,欢迎来到仪器设备网! [登录] [免费注册]
仪器设备网
位置:首页 > 产品库 > Dalfopristin(mesylate)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Dalfopristin(mesylate)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Dalfopristin(mesylate)图片
规格:98%
分子量:787.0
包装与价格:
包装价格(元)
1mg电议
5mg电议

产品介绍
streptogramin antibiotic
货号:ajcx11298
CAS:
分子式:C34H51N4O9S ? CH3SO3
分子量:787.0
溶解度:Soluble in ethanol;methanol;DMSO;dimethyl formamide
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Dalfopristin (mesylate) is a streptogramin antibiotic and a 50S ribosome inhibitor [1][2].

Streptogramins are produced by a variety of Streptomyces sp as a mixture (ratio of 7:3) of two chemically unrelated compounds, type A and B. Dalfopristin, the type A Streptogramin, is often combined with type B streptogramin antibiotic, quinupristin, to produce Quinupristin-Dalfopristin Complex, known commercially as Synercid. Synercid is used to treat skin infections, and is also active against some Gram-negative and anaerobic bacteria [2][3].

The ribosome is composed of two ribonucleoprotein subunits, the 50S and 30S. The 50S ribosome inhibitors inhibited protein synthesis [2].

Dalfopristin is a cyclic polyunsaturated macrolactone that interferes with binding of tRNA substrates to both A- and P-sites [2]. Dalfopristin blocked the access of peptidyl-tRNAs to the ribosome and peptidyltransferase elongation reaction in bacteria [1]. quinupristin and dalfopristin acted synergistically to kill Gram-positive bacteria, as well as some Gram-negative and anaerobic bacteria [2][3]. Dalfopristin hydrolyzed rapidly to virginiamycin M under physiological conditions.

参考文献:
[1].  Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010 Jun;8(6):423-35.
[2].  Wilson DN. The A-Z of bacterial translation inhibitors. Crit Rev Biochem Mol Biol. 2009 Nov-Dec;44(6):393-433.
[3].  Noeske J, Huang J, Olivier NB, et al. Synergy of streptogramin antibiotics occurs independently of their effects on translation. Antimicrob Agents Chemother. 2014 Sep;58(9):5269-79.